logo

For the Inventor, By the Inventor

Kusatsu, Japan

Nobutoshi Yamada

This inventor holds 22 USPTO granted patents, plus 2 CIPO patents, primarily in Pharmaceutical Compositions. Top assignees: Ishihara Sangyo Kaisha, Ltd., The Green Cross Corporation, Research Association for Biotechnology of Agricultural Chemicals. Active years: 1987-1996.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nobutoshi Yamada. Retrieved from https://idiyas.com/inventor/nobutoshi-yamada

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.1

ph-index = 8

Forward Citations = 244(Granted Patents)


Location History:

  • Moriyama, JP (1987 - 1991)
  • Shiga, JP (1991)
  • Otsu, JP (1992)
  • Kusatsu, JP (1989 - 1996)

Company Filing History:

goldMedal21 out of 394 
 
Ishihara Sangyo Kaisha, Ltd.
 patents
silverMedal6 out of 264 
 
The Green Cross Corporation
 patents
bronzeMedal1 out of 4 
 
Research Association for Biotechnology of Agricultural Chemicals
 patents
where one patent can have more than one assignee

Years Active: 1987-1996

Loading Chart...
Loading Chart...
Areas of Expertise:
TNF Muteins
Pharmaceutical Compositions
Benzoylurea Compounds
Antitumor Agents
Peptide Salts
Genetic Engineering
Titanium Oxide Powder
Chartreusin Derivatives
Autoimmune Hyperthyroidism
N-benzoyl Compounds
Powdery Formulations
Substituted Benzene Derivatives
22 patents (USPTO):Explore Patents
1. 5519119 - Muteins of TNF pharmaceutical compositions and a method of making (1996-05-21),
2. 5446129 - Peptide or its salt for autoimmune hyperthyroidism containing it (1995-08-29),
3. 5247070 - N-terminal muteins of tumor necrosis factor (1993-09-21),
4. 5149793 - Exo-3',4'-O-benzylidene-3'-demethylchartreusin and its salts (1992-09-22),
5. 5147686 - Method of making titanium oxide powder having antimicrobial metal (1992-09-15),
6. 5145775 - Polyhedrin gene and genetic engineering thereof (1992-09-08),
7. 5116949 - Benzoyl urea compound-albumin complex (1992-05-26),
8. 5102884 - Substituted benzoylurea compounds or their salts, processes for their (1992-04-07),
9. 5098907 - Powdery pharmaceutical composition containing benzoyl urea, a dispersant (1992-03-24),
10. 5064945 - Chartreusin derivatives and salts thereof (1991-11-12),
11. 5002952 - Readily absorbed pharmaceutical composition (1991-03-26),
12. 4987135 - Substituted benzene derivatives, processes for their production and (1991-01-22),
13. 4983605 - Pharmaceutical composition (1991-01-08),
14. 4927919 - Chartreusin derivatives and salts thereof (1990-05-22),
15. 4904668 - Benzoyl urea compound (1990-02-27),

Title: Innovations and Contributions of Nobutoshi Yamada

Introduction: Nobutoshi Yamada, an esteemed inventor based in Kusatsu, Japan, has made significant contributions to the field of pharmaceuticals with a notable portfolio of 22 patents. His work primarily focuses on innovative biopharmaceutical compositions and methods that target various medical conditions.

Latest Patents: Yamada's latest patents include advancements in pharmaceutical compositions related to tumor necrosis factor (TNF). One of his noteworthy inventions is a polypeptide featuring an amino acid sequence that encompasses critical functional regions of TNF. This invention notably includes a method of producing a recombinant plasmid containing DNA that encodes for this polypeptide. Additionally, his research has led to the development of a specific peptide for autoimmune hyperthyroidism, demonstrating his commitment to tackling complex health issues through innovation.

Career Highlights: Throughout his career, Yamada has been associated with prominent companies in the industry. He has worked at Ishihara Sangyo Kaisha, Ltd. as well as The Green Cross Corporation, contributing his expertise in biotechnology and pharmaceuticals. His work has positioned him as a key player in the advancement of medical treatments, impacting both clinical practices and patient outcomes.

Collaborations: Yamada has collaborated with notable peers such as Hideo Sugi and Takahiro Haga. These partnerships have enhanced his research endeavors, leading to groundbreaking discoveries and innovations in the biopharmaceutical sector.

Conclusion: Nobutoshi Yamada remains a significant figure in the realm of pharmaceutical innovations. His extensive experience and impressive patent portfolio exemplify his dedication to advancing medical science. Through his inventions and collaborations, Yamada continues to impact the field, paving the way for future innovations in treatments and therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…